As healthcare providers and institutions switch to a value based care system, how will healthcare and life science innovators navigate this paradigm shift? Will your new therapeutic/device/diagnostic be groundbreaking enough to be worthy of procurement in a risk sharing environment? How will you change your reimbursement strategies during the development process?
Come and learn about MIPS, APM, MACRA and a whole host of new acronyms for your glossary!
Share your story as to why you think your innovation is well poised for the value based program.